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Incidence of Fragile X Syndrome
by Newborn Screening for Methylated FMR1 DNA
Bradford Coffee,1 Krayton Keith,1 Igor Albizua,1 Tamika Malone,1 Julie Mowrey,1
Stephanie L. Sherman,1 and Stephen T. Warren1,2,*
Fragile X syndrome (FXS) results from a CGG-repeat expansion that triggers hypermethylation and silencing of the FMR1 gene. FXS is
referred to as the most common form of inherited intellectual disability, yet its true incidence has never been measured directly by large
population screening. Here, we developed an inexpensive and high-throughput assay to quantitatively assess FMR1methylation in DNA
isolated from the dried blood spots of 36,124 deidentiﬁed newborn males. This assay displays 100% speciﬁcity and 100% sensitivity for
detecting FMR1methylation, successfully distinguishing normal males from males with full-mutation FXS. Furthermore, the assay can
detect excess FMR1 methylation in 82% of females with full mutations, although the methylation did not correlate with intellectual
disability. With amelogenin PCR used for detecting the presence of a Y chromosome, this assay can also detect males with Klinefelter
syndrome (KS) (47, XXY). We identiﬁed 64 males with FMR1 methylation and, after conﬁrmatory testing, found seven to have full-
mutation FXS and 57 to have KS. Because the precise incidence of KS is known, we used our observed KS incidence as a sentinel to assess
ascertainment quality and showed that our KS incidence of 1 in 633 newborn males was not signiﬁcantly different from the literature
incidence of 1 in 576 (p ¼ 0.79). The seven FXS males revealed an FXS incidence in males of 1 in 5161 (95% conﬁdence interval of 1 in
10,653–1 in 2500), consistent with some earlier indirect estimates. Given the trials now underway for possible FXS treatments, this
method could be used in newborn or infant screening as a way of ensuring early interventions for FXS.Introduction
Fragile X syndrome (FXS [MIM 300624]) is caused bymuta-
tions of the X-linked FMR1 (MIM 309550) gene, which
results in the functional absence of the gene product,
FMRP.1–3 The most common mutation of FMR1 is the
expansion of a CGG trinucleotide repeat in the 50 untrans-
lated region of the gene. Expansions of more than 200
CGG repeats, known as the full mutation, result in
FMR1 hypermethylation and chromatin condensation,
which lead to transcriptional silencing.4–7 Expansion to
the full mutation occurs when premutation alleles (from
55 up to 200 CGG repeats) are transmitted maternally to
offspring. Initially, carriers of premutation alleles were
believed to lack a clinical phenotype, but we now appre-
ciate that approximately 25% of female premutation
carriers have fragile X-associated primary ovarian insufﬁ-
ciency (FXPOI [MIM 311360]).8 Moreover, fragile X-associ-
ated tremor/ataxia syndrome (FXTAS [MIM 300623]) is
often encountered in older men who are carriers of the
FMR1 premutation.9 These adult-onset disorders found in
premutation carriers are distinct from FXS and, at least
for FXTAS, are believed to be RNA-mediated, not due to
the reduction or absence of FMRP.10
Initial prevalence of FXS estimates, based on induction
of the Xq27.3 fragile site (FRAXA) as a cytogenetic marker
for the disorder, described the prevalence of FXS to be 1 in
1000 to 1 in 2610 males.11,12 After the discovery of the
FMR1 gene in 1991 and the eventual molecular diagnostic
test for FXS, these initial prevalence estimates were revised
to ~1 in 4000 males.13 Studies since that time have esti-mated the prevalence to range from 1 in 3717 to 1 in
8918 in the general population of European descent
(summarized in Crawford et al.).14 The largest of these
studies identiﬁed 20 males with FXS among 3738 boys in
special education classes in the United Kingdom, yielding
a general population prevalence of 1 in 5530.15 Another
study by Crawford et al., surveying children with special
education needs in the metropolitan area of Atlanta, GA,
USA, estimated the prevalence of FXS at 1 in 3717 among
males of European descent and 1 in 2545 among African
American males.16 Among the 39 published studies, the
average sample size was only 405 individuals (range: 53–
3738), leading to exceptionally large conﬁdence intervals
(CIs). In addition, all of these estimates are indirect, given
that they are extrapolations from different phenotypically
deﬁned patient populations, each surveying a small
number of individuals. Furthermore, most of these studies
have focused on populations of European descent, and
there is limited information on the frequency of FXS in
other racial or ethnic groups. For a more accurate deﬁni-
tion of the incidence of FXS both in the general population
and in racial or ethnic subgroups, a large screen of the
general population, such as a newborn screen, is needed.
One requirement of a population screen for FXS is an
inexpensive assay that is also highly sensitive and accurate.
Although southern blot analysis of the CGG repeat is
deﬁnitive, it is also expensive, low-throughput, and tech-
nically challenging in newborn screening environments.
PCR across the CGG repeat is another possible assay, but
in general, its sensitivity declines as the repeat lengthens
into the full-mutation range, often resulting in the1Department of Human Genetics, 2Departments of Pediatrics and Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
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undesirable situation of a positive outcome being the
absence of signal. Recent technical improvements, such
as capillary southern analysis17 and a PCR method using
a chimeric primer that randomly targets the CGG repeat,
producing a smear after agarose gel electrophoresis,18
have been shown to detect CGG repeat expansions in
the full-mutation range in DNA samples isolated from
whole blood. Fernandez-Carvajal et al. recently used
a two-tiered screening strategy of standard PCR ampliﬁca-
tion of the CGG repeat followed by the chimeric primer
assay to screen 5267 dried blood spot samples from males
from Spain.19 Of the 5267 samples, two failed to produce
PCR products by the standard CGG repeat PCR. Follow-
up testing of these two samples with the use of the
chimeric primer assay suggested that these individuals
had full-mutation expansions. Fernandez-Carvajal et al.
estimate a FXS incidence of 1 in 2633 males, but with
rather broad CIs (95% CI 1 in 10,000 to 1 in 714).
One of the epigenetic changes concomitant with CGG
repeat expansion is DNA methylation.4 Full-mutation
alleles are densely methylated, not only at the CpGs
located within the CGG tract but also at CpGs in the ﬂank-
ing sequence, including the FMR1 promoter. In male FXS
patients with the full mutation, as well as mosaic males
with FXS, virtually every cytosine in each CpG in the
promoter of FMR1 becomes methylated, whereas there is
a complete absence of methylation in unaffected males.20
Thus, FMR1 DNA methylation can be used as a marker for
FXS in males.
The traditional method for assessing DNA methylation
is by southern analysis with the use of methylation-sensi-
tive restriction enzymes, which provides information
about CGG repeat length as well as methylation. Alterna-
tively, sodium bisulﬁte conversion of DNA coupled
with methylation-sensitive PCR (MSP)21 or methylation-
speciﬁc multiplex ligation-dependent probe ampliﬁcation
(MLPA)22 can also assess DNA methylation. MSP is less
labor intensive than southern analysis and, along with
CGG repeat sizing by PCR ampliﬁcation, is used in clinical
testing for FXS in males. Importantly, MSP is amenable to
high-throughput analysis, allowing for the assessment of
FMR1 DNA methylation in a large cohort of samples.
In normal females, one of the two copies of FMR1 is
methylated because of X chromosome inactivation.23
Therefore, normal females have a 1:1 ratio of methylated
to unmethylated FMR1 DNA. In females who carry a full
mutation, without the skewing of X chromosome inacti-
vation, the ratio of methylated to unmethylated FMR1
DNA will shift from 1:1 (50%:50%) to 3:1 (75%:25%).
Therefore, the quantiﬁcation of FMR1 methylation could
also lead to the identiﬁcation of females who carry the
full mutation. However, unlike males with the full muta-
tion, not all females who carry a full mutation have intel-
lectual disability. In a study by Rousseau et al., 41% of
full-mutation carrier females had no degree of intellectual
disability, in comparison to 100% of full-mutation males
being intellectually disabled.24 However, it is important504 The American Journal of Human Genetics 85, 503–514, Octoberto recognize that intellectual disability is not the only
expression of the full mutation. For example, a study
by Freund et al.25 examined the prevalence of psychiatric
disorders among a cohort of 17 females who carry full
mutations and found that there was an increase in the
prevalence of several psychiatric diagnoses, such as avoi-
dant personality disorder, mood disorder, and stereotypy/
habit disorder, in the full-mutation-carrying females as
compared to controls. Although the study is limited in
size, if these disorders other than intellectual disability
are truly due to the full mutation, then disease pene-
trance in full-mutation-carrying females may approach
100%.
Here, we describe a sensitive, rapid, low-cost, and quan-
titative methylation-sensitive PCR (Q-MSP) method that is
amenable to high-throughput analysis for detection and
quantiﬁcation of FMR1 DNA methylation directly from
newborn dried blood spots. Q-MSP can detect FMR1 at
exceptionally low levels of FMR1 methylation—less than
1%methylated FMR1DNA—easily detecting full-mutation
and mosaic males with FXS. The sensitivity of the assay
allows for a sample pooling strategy, thereby reducing
the cost of population screening. To test the feasibility of
using Q-MSP to screen for FXS and to provide a more accu-
rate estimate of FXS incidence, we screened the dried blood
spots of 36,124 deidentiﬁed males from the Georgia Public
Health Laboratory Newborn Screening Program for FMR1
DNA methylation.
Material and Methods
Dried Blood Spot Samples
Dried blood spots were collected from the Georgia Public Health
Laboratory Newborn Screening program from April 2006 to
September 2008. Each sample was collected sequentially after
the state had completed all newborn screening. The samples
were deidentiﬁed, with only the gender and the race or ethnicity
being recorded. Three-millimeter dried blood spot punches were
collected in triplicate in 96-well plates with the use of a Wallac
DBS Puncher (Perkin Elmer) and stored at room temperature.
The Emory University and the Georgia Department of Human
Resources institutional review boards approved this study.
Sodium Bisulﬁte Treatment of Genomic DNA
Sodium bisulﬁte treatment was performed essentially as described
previously.26 In brief, 1 mg of genomic DNA isolated from periph-
eral blood lymphocytes was diluted in 25 ml dH2O. The DNA was
denatured by the addition of 2.75 ml of 2 N NaOH, ﬁnal concentra-
tion of 0.2 N NaOH, and incubated at 37C for 10min. After dena-
turation, 15 ml of freshly prepared 10 mM hydroquinone (Sigma
catalog no. H9003) and 260 ml of 3.6 M sodium bisulﬁte pH~5.0
(Sigma catalog no. 243973) were added and the reaction layered
with mineral oil and incubated 4–16 hr at 54C. A modiﬁcation
of the protocol for theWizard SV Genomic DNA Clean-Up System
(Promega A2361) was used for isolation of the DNA after sodium
bisulﬁte treatment. In brief, 300 ml of a 1:1 mix of SV lysis buffer
and 95% ethanol was mixed with the ~300 ml of sodium bisulﬁte
reaction. This mixture was transferred to a spin column and9, 2009
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Figure 1. FMR1 Promoter Sequence Tar-
geted for DNA Methylation Analysis
The sequence of the FMR1 promoter from
position 192 to position þ59 is shown.
The top line is the genomic reference
(Ref.). The second line represents the
sequence after sodium bisulﬁte treatment
and PCR ampliﬁcation if every cytosine
in each CpG is methylated (Meth.). The
third line represents the sequence after
sodium bisulﬁte treatment and PCR
ampliﬁcation if every cytosine in each
CpG is unmethylated (Unmeth.). The
ampliﬁcation primers are underlined, and
the TaqMan probes are indicated by the
shaded boxes. The CpGs targeted by the
TaqMan probes are underlined and in
bold. The transcription start site is indi-
cated by the arrow.centrifuged for 1 min, binding the DNA to the resin within the
column. The sample was washed two times with 600 ml of SV
wash buffer. The column was centrifuged one more time without
wash buffer for the removal of residual buffer and transferred to
a new 1.5 ml microfuge tube. The DNA was eluted from the
column by the addition of 50 ml of H2O, followed by centrifuga-
tion for 1min. The DNA eluted from the columnwas desulfonated
by the addition of 5.5 ml 3N NaOH and incubation at room
temperature for 5 min. The DNAwas ethanol precipitated, washed
once with 75% ethanol, and suspended in 50 ml of 10mMTris-HCl
(pH 8.0).
Sodium Bisulﬁte Treatment of Dried Blood Spots
Individual Samples
Dried blood spot punches in a 96-well plate were boiled in 60 ml of
1% SDS for 10 min for lyse of the cells and release of the DNA.
After boiling, the samples were centrifuged and 25 ml of the super-
natant transferred to a fresh 96-well plate. This extract was then
treated with sodium bisulﬁte as described above.
Pooled Samples
Dried blood spot punches were pooled into groups of 44 individ-
uals. There were two 3 mm punches per individual, for a total of
88 dried blood spot punches per pool. DNA was extracted from
the pooled sample with the Wizard SV Genomic DNA Puriﬁcation
System (catalog no. A2361). In brief, 1500 ml of Wizard Nuclei
Lysis Buffer was added to the dried blood spots, followed by
300 ml of 0.5 M ethylenediaminetetraacetate (EDTA) (pH 8.0).
The sample was heated at 90C for 10 min and then cooled to
room temperature, and 150 ml of 25 mg/ml proteinase K solution
was added. The sample was incubated overnight at 55C. The next
day, the sample was centrifuged, and 680 ml of supernatant was
removed. An equal volume of Wizard SV Lysis Buffer was added
to the supernatant and mixed. The sample was centrifuged at
14,000 rpm in microfuge for 1 min at room temperature. The
supernatant was transferred to the 96-well binding column plate,
and a vacuum was applied, pulling the sample through the
column. The sample was washed four times with the Wizard SV
96 wash solution and dried with the vacuum for 10 min. The
96-well binding column plate was transferred to a new 96-well
plate, and the DNA was eluted by the addition of 80 ml of water
preheated to 65C and application of a vacuum.The AmerFor pooled dried blood samples, sodium bisulﬁte treatment was
performedwith theEpiTect96BisulﬁteKit (QIAGEN) inaccordance
with the manufacturer’s protocol. This procedure was found to
result in a higher yield of DNA after bisulﬁte treatment than the
traditional homebrew method described above. In brief, 20 ml of
extracted DNA was treated with 85 ml of bisulﬁte solution and
35ml ofDNAprotect buffer. The samplewas incubated on a thermal
cycler under the following conditions: initial denaturation at 99C
for 5 min, followed by 60C for 25 min, 99C for 5 min, 60C for
85 min, 99C for 5 min, and 60C for 175 min. After sodium
bisulﬁte treatment, 560 ml of BL solution with 10 mg/ml of carrier
RNA was added, and the sample was transferred to the 96-well
binding plate and pulled through the columns with a vacuum.
The columns were washed with 500 ml Wash Buffer. The bisulﬁte-
treated DNA was desulfonated on the column by the addition of
250 ml of BD solution and incubation at room temperature for
15 min. The desulfonated DNA bound to the column was washed
two times with Wash Buffer followed by one wash with 95%
ethanol. The columns were dried for 10 min under the vacuum.
The 96-well binding plate was transferred to a collection plate,
and 70 ml of Buffer EB and 10 ml of Top Elute were added to each
column. A vacuum was applied for 1 min for elution of the DNA.
The bisulﬁte-treated DNAwas stored at 80C.
Real-Time TaqMan Methylation-Sensitive PCR
Primer and Probe Design for FMR1
All primers for the TaqMan MSP were synthesized by Integrated
DNA Technologies. The ampliﬁcation primers used in the real-
time TaqMan methylation-sensitive PCR reaction were designed
to avoidCpGdinucleotides in the sense strandwithin thepromoter
of the FMR1 gene (Figure 1). The FMR1 ampliﬁcation primers
are: FMR1F 50-GYGTTTTTAGGTTATTTGAAGAGAGAGGG-30 and
FMR1R 50-CRACCCRCTACRAATATAAACACTAAAACC-30 (Y¼ Tor
C; R ¼ G or A). The TaqMan probes FMR1M2 (methylated DNA-
speciﬁc probe) and FMR1U3 (unmethylated FMR1 DNA-speciﬁc
probe) target a sequence from positions 97 to 72, relative to
the transcription initiation site for FMR1. FMR1M2 (50-CGGGG
TCGAGGGGTTGAGTTCGCG-30) is 50-end labeled with Fam and
is quenched by the addition of Black Hole Quencher 1 to the 30
end of the oligonucleotide. FMR1U3 (50 - TGGGGTTGAGGGGTTG
AGTTTGTGGG - 30) is 50 end-labeled with Hex and quenched byican Journal of Human Genetics 85, 503–514, October 9, 2009 505
the addition of Black Hole Quencher 1 to the 30 end of the oligonu-
cleotide. Bisulﬁte-treated DNAs were subjected to TaqMan PCR
ampliﬁcation in a 25 ml volume with the above primers and probes
with the use of Invitrogen PlatimumTaqDNApolymerasewith the
manufacturer’s suggested buffer and 1.5 mM ofMgCl2. The primer
concentrations were 1 mM and the probe concentrations were
150 nM. The PCR conditions were an initial 95C denaturation
for 3 min followed by ampliﬁcation cycles consisting of 95C for
10 s, 67C for 30 s, and 72C for 60 s for 40 cycles.
Amelogenin PCR
Male samples determined to have methylated FMR1 DNA were
tested for veriﬁcation of the gender via amelogenin PCR ampliﬁca-
tion. The amelogenin loci on the X and Y chromosomes carry
homologous sequences that, when targeted by PCR, yield two
differently sized products: a 542 base pair (bp) product from the
X chromosome and a 358 bp product from the Y chromosome.
The amelogenin primers used were AmelF (50-CTCTGATGGTT
GGCCTCAAG-30) and AmelR (50-ACCTTGCTCATATTATACTTGA
CAAAG-30). PCR ampliﬁcation was done with the use of Invitro-
gen Platinum Taq DNA polymerase with the manufacturer’s rec-
ommended buffer and 3.5 mM MgCl2 and primer concentrations
of 333 nM. After an initial denaturation step of 95C for 3min, the
cycling conditions were 95C for 30 s, 58C for 45 s, and 72C for
45 s for 35 cycles, followed by a ﬁnal extension step of 72C for
7 min. The PCR products were resolved by electrophoresis on
a 1.5% agarose gel.
CGG Repeat Analysis
CGG repeat length was determined by PCR ampliﬁcation with the
use of the forward primer FXCFOR (50-AGGCGCTCAGCTCCGTT
TCGGTTTCACTTC-30) and the Fam-labeled FXX3 reverse primer
(50-FAMGTGGGCTGCGGGCGCTCGAGG-30). The PCR reaction
conditions were as follows: 42%Q-Solution (QIAGEN), 2%DMSO,
13 PCR Buffer II (Roche), 2 mM MgCl2, 150 mM 7-deaza-dGTP,
48 mM dGTP,192 mM dATP, dTTP, cCTP, and 1.25 units of Taq DNA
polymerase (Roche). The cycling parameters, after an initial dena-
turation step of 10 min at 95C, were as follows: 95C for 90 s,
67C for 60 s, and 72C for 3 min for 24 cycles, followed by a ﬁnal
extension at 72C for 10 min. The PCR products were separated
by capillary electrophoresis with an ABI 3100 Genetic Analyzer
(ABI).
Southern Analysis
Southern analysis of males conﬁrmed by amelogenein PCR was
done with the use of genomic DNA isolated from the dried blood
spot card. Residual dried blood from the newborn screening card
was collected and boiled with 1 ml of 1% SDS for 10 min. The
sample was centrifuged and the supernatant collected. Five
hundredmicrograms of proteinase K was added to the supernatant
and incubated overnight at 55C. The sample was phenol
extracted three times, followed by one chloroform extraction.
The DNA was precipitated by the addition of 1/10 volume of 3M
sodium acetate and 2.5 volumes of ethanol, followed by incuba-
tion at 80C from 1 to 16 hr. The DNA was pelleted by centrifu-
gation, washed with 70% ethanol, and eluted in 10 ml TE.
Approximately 4 mg of isolated genomic DNA was digested in
a 50 ml reaction with 40 units of EcoRI and 40 units of XhoI
(New England Biolabs) with the use of the manufacturer’s recom-
mended buffer for approximately 16 hr. After 16 hr, 1 ml (10 units)
of both EcoRI and XhoI were spiked into the reaction, and the506 The American Journal of Human Genetics 85, 503–514, Octoberdigestion continued for an additional 4 hr. The digested DNAs
were separated by electrophoresis on a 1% agarose gel. The DNA
was transferred to a Hybond Nþ nylon membrane (Amersham)
by capillary transfer with the use of the TurboBlotter system
(Whatman). After transfer, the membrane was baked for 2 hr
at 80C so that the DNAwas ﬁxed to the membrane. Prehybridiza-
tion of the membrane was performed at 65C with a hybridiza-
tion solution (7% SDS, 1.53 SSC, 100 mg/ml polyethylene glycol
[PEG] 8000, 250 mg/ml heparin) containing 430 mg/ml of salmon
sperm DNA. Hybridization was performed with the use of the
FMR1 probe A, a PCR product generated from the FMR1 promoter.
The probe was labeled with alpha 32P-dATP with the High Prime
Reaction kit (Roche). 1 3 107 cpm of labeled FMR1 probe A in
10 mls of hybridization solution containing 400 mg/ml of salmon
sperm DNA was added to the membrane and rotated at 65C for
16 hr. After hybridization, the membrane was washed once with
Wash Buffer I (0.1% SDS, 23 SSC) at room temperature and once
at 65C, followed by one wash with Wash Buffer II (0.5% SDS,
0.13 SSC) at 65C. The membrane was sealed in plastic wrap
and exposed to ﬁlm and/or Storm Phosphorimager screen (Molec-
ular Dynamics).
Results
We have developed a Q-MSP assay that can be used for the
detection of aberrant FMR1 methylation as a screen for
FXS. First, we present the validation of detecting FMR1
methylation in isolated male genomic DNA, as well as in
male dried blood samples. Second, we test whether quanti-
ﬁcation of FMR1 methylation by Q-MSP can be used for
the identiﬁcation of full-mutation carrier females and
whether the detected amount of FMR1 methylation in
a full-mutation carrier female correlates with the pheno-
type. Third, we examine the sensitivity of Q-MSP with
respect to pooling male dried blood samples for efﬁcient
screening for FXS. Finally, to demonstrate the utility of
the method for newborn screening in males, we provide
results from screening 36,124 deidentiﬁed male dried
blood samples for FMR1 methylation with respect to the
identiﬁcation of males with FXS and with KS.
Development and Validation of Q-MSP as a Screen
for FXS
Detection and Quantification of Methylated FMR1 DNA in Males
To verify that Q-MSP can be used for detection of methyl-
ated FMR1 DNA, we took genomic DNAs isolated from
blood from 25 clinically documented FXS males (22 full-
mutation carriers and three mosaic) and treated them
with sodium bisulﬁte, then subjected the treated DNAs to
Q-MSP targeting FMR1. We also included three clinically
documented KS males, because these males would also
show FMR1 methylation because of their inactive X chro-
mosome. As shown in Figure 2, Q-MSP can easily detect
FMR1 DNA methylation in males with both FXS and KS.
As expected, the proportion of methylated FMR1 DNA is
considerably less in KS males, who carry both methylated
and unmethylated FMR1 DNA on the inactive and active
X chromosomes, respectively, as opposed to males with9, 2009
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Figure 2. Proportion of Methylated FMR1 DNA Detected in 25 Different FXS Males and Three KS Males
Methylated FMR1 DNA was quantiﬁed by Q-MSP and is expressed as the percentage of methylated DNA (amount of methylated FMR1
DNA / amount of methylated FMR1 DNA þ amount of unmethylated FMR1 DNA). The height of the bar corresponds to the mean
amount of methylated FMR1 DNA from three measurements, with the error bars representing 1 SD.FXS, whose single copy of the FMR1 gene is completely or
predominantly methylated.
To screen for FXS in the large cohort of samples neces-
sary for a population-based study, we adapted this proce-
dure to a 96-well format, using crude extracts from dried
blood spots as starting material. To validate the assay, we
screened 88 3mmdried blood spots frommales (86 normal
males and twomosaic FXSmales) simultaneously for FMR1
DNA methylation. The investigators were blinded to the
location of the mosaic FXS dried blood spots within the
96-well plate. As shown in Figure 3, the two mosaic FXS
male samples had signiﬁcant amounts of FMR1DNAmeth-
ylation that was easily detected by Q-MSP, whereas the 86
normal males had no detectable FMR1 DNA methylation.
Importantly, unmethylated FMR1 DNA was detected in
all of the samples, verifying that the absence of signal formethylated FMR1 DNA in the negative samples was not
due to any failure of PCR ampliﬁcation.
Quantification of Methylated FMR1 DNA in Females
In full-mutation females, skewing of X chromosome inac-
tivation can alter the proportion of methylated FMR1DNA
from as low as 50% (completely favorably skewed; i.e., the
inactive X chromosome always carries the mutated FMR1
gene) to 100% (completely unfavorably skewed; i.e., the
active X chromosome always carries the mutated FMR1
gene). Therefore, a female with an elevated amount of
methylated FMR1 DNA is at higher risk of carrying a full-
mutation FMR1 allele.
To determine whether we could distinguish between
normal females and full-mutation females, we used Q-MSP
to quantify the proportion of methylated FMR1 DNA in
a cohort of normal and full-mutation females (Figure 4).mosaic fragile X males
normal males
Methylated FMR1 DNA
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Figure 3. Amplification Plots for 88Male
Dried Blood Spot Samples Tested Simulta-
neously via Q-MSP for Methylated FMR1
DNA
Right panel: ampliﬁcation plot for Fam-
labeled TaqMan probe speciﬁc for methyl-
ated FMR1 DNA. Left panel: ampliﬁcation
plot for Hex-labeled TaqMan probe speciﬁc
for unmethylated FMR1 DNA. Each line
represents a single sample.
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Figure 4. Quantification of Methylated FMR1 DNA in 33 Females Who Carry the Full-Mutation Allele
The proportion of methylated FMR1DNAwas quantiﬁed by Q-MSP and is expressed as a percentage of total FMR1DNA. Thirteen normal
females with normal FMR1 alleles are represented by the green bars on the right-hand side of the graph. The 33 females carrying the full
mutation are represented as follows: affected full mutation, red bars; unaffected full mutation, dark blue bars; and full mutation with no
phenotypic information, white bars. The height of the bar corresponds to the mean amount of methylated FMR1 DNA from three
measurements, with the error bars representing 1 SD. The normal range of methylation (normal female mean 5 2 SD) is represented
by the shaded box.The mean proportion of methylated FMR1 DNA for 13
normal females was 0.59, with a standard deviation (SD)
of 0.07. The slight increase from the predicted 0.50 is
probably due to cross hybridization of the TaqMan probe
speciﬁc for methylated DNA with unmethylated DNA.
Assuming a normal distribution of methylation, we esti-
mate from this data set that the percentage of methylated
FMR1 DNA in 95% of normal females will be between 0.45
and 0.73. The mean percentage of methylated FMR1 DNA
from a cohort of 33 females carrying the full mutation is
0.80, with a SD of 0.09. Thus, the percentage of methylated
FMR1 DNA is signiﬁcantly elevated among females who
carry the full mutation (p ¼ 5.4 3 109). We found 27 out
of the 33 full-mutation females (82%) have an increased
percentage of methylated FMR1 DNA of greater than 2
SD above the normal mean. Assuming a normal distribu-
tion, 2.5% of normal females would theoretically exceed
this cutoff, resulting in a positive predictive value of 97%
for detecting full-mutation females.
The incomplete penetrance of the full mutation in
females is believed to be due to the skewing of X chromo-
some inactivation, speciﬁcally in the brain. In this cohort
of females carrying the fullmutation, 24hadbeen clinically
assessed, 19 of whom were classiﬁed as affected and ﬁve as
unaffected. Of the 19 full-mutation females affected with
FXS, 15 had elevated FMR1 DNA methylation of more
than 2 SD above the mean (79%). Of the ﬁve full-muta-
tion-carrying females unaffected by FXS, four had elevated
FMR1 DNA methylation of greater than 2 SD above the
mean (80%). These data indicate that the probability that
an unaffected female carrying the full mutation has
elevated FMR1DNAmethylation is approximately the same
as the probability that an affected full-mutation carrier has
elevated FMR1 DNA methylation. Therefore, although
methylated FMR1 DNA can detect most full-mutation-
carrying females, the test has little prognostic value.508 The American Journal of Human Genetics 85, 503–514, OctoberPooling of Male Dried Blood Spot Samples for FMR1 DNA
Methylation Screening
Q-MSP is very sensitive, and in experiments in which
genomic DNAs from FXS males and normal males are
mixed, methylated FMR1 DNA can easily be detected
when as little as 0.5% of a sample is from an FXS male
(Supplemental Data, available online; Figure 1). In a popu-
lation screen, the vast majority of males will test negative
for the presence of methylated FMR1 DNA. Given the
sensitivity of the assay, we reasoned that we could pool
male samples together in a single tube, because only
a limited number of pools would have methylated FMR1
DNA. If no FMR1 DNA methylation is detected, then all
samples in that pool screen negative and no further testing
is done; however, if FMR1 DNA methylation is detected in
the pool, then the positive sample within the pool can be
identiﬁed and tested individually so that the presence of
the full mutation can be determined.
To test this idea, we added one dried blood spot from
a mosaic FXS patient to 95 dried blood spots from normal
males in a single tube. DNA was extracted from the pooled
dried blood spots and treated with sodium bisulﬁte. As
a control, we also extracted DNA from a pool of 96 normal
males. We easily detected the methylated FMR1 DNA from
the single mosaic FXS male sample among the 95 dried
blood spots from normal males (Figure 5). Thus, up to
~100 males could be screened simultaneously for methyl-
ated FMR1 DNA, at substantial labor and cost savings. In
addition, as a quality control during the screening, we
used pools of 43 dried blood spots from normal males
that were spiked with a dried blood spot from either a sin-
gle FXS or KS male, in addition to a control pool that con-
tained dried blood spots from only normal males. Seven
different spiked pools tested had FMR1 methylation
detected by Q-MSP, whereas the pools that contained only
normal males never had detectable FMR1 methylation9, 2009
(Supplemental Data; Figure 2). Moreover, of these seven
independent spiked pools, each was also used multiple
times as a control, for a total of 39 replications without
discrepancy. These results demonstrate 100% sensitivity
and 100% speciﬁcity for this method of detecting the full
mutation in males.
Screening Deidentiﬁed Dried Blood Spots
from the Georgia Public Health Laboratory
State-mandated newborn screening programs offer an
opportunity to screen a large, unbiased collection of indi-
viduals from the general population. From the Georgia
Public Health Laboratory, we collected 36,124 male dried
blood samples after the completion of all newborn
screening. The gender and racial or ethnic information
from the demographic portion of the newborn screening
card was recorded for each sample, and all other identi-
fying information was discarded. The racial and ethnic
diversity of these samples was as follows: 45% white;
30% African American; 15% Hispanic; 2% Asian; 2%
multiracial; < 1% American Indian; and 5% unknown or
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Figure 5. Amplification Plots of Pools of 96 Male Dried Blood
Spot Samples with or without a Mosaic Male with FXS
The red lines represent the pooled sample containing one mosaic
FXS male dried blood spot mixed with 95 dried blood spots from
normal males. The blue lines represent the sample containing 96
dried blood spots from normal males.
(A) Ampliﬁcation plot for TaqMan probe speciﬁc for methylated
FMR1 DNA.
(B) Ampliﬁcation plot for TaqMan probe speciﬁc for unmethylated
FMR1 DNA.The Amerunmarked. These percentages closely mirror the percent-
ages reported by the Centers for Disease Control in the
Vital Statistics Report for the state of Georgia in 2005,
indicating that we have a random and accurate sampling
of the newborns in the state.
Three-millimeter punches of dried blood samples were
collected in triplicate in three 96-well plates, each plate
containing 88 males with two punches each (a total of
176 punches). Samples from 44 males (88 dried blood
spots) were pooled so that each plate contained two pools
of 44 samples. If a pool contains no detectable methylated
FMR1 DNA, then all 44 samples within that pool are
called negative and no further testing is done. For pools
that have detectable methylated FMR1 DNA, the replicate
plates are used for identifying the positive individual by
screening of a pool of four rows of 11 samples in one
replicate plate and pooling of 11 columns of four samples
in the other replicate plate. Thus, 15 reactions can iden-
tify the positive individual(s) within that pool of 44
samples.
The remainder of the dried blood spot cards from indi-
viduals withmethylated FMR1DNAwere used for isolating
genomic DNA for further testing. The gender of the indi-
vidual was determined via amelogenin PCR. Males with
FMR1 DNA methylation were tested individually by
Q-MSP for veriﬁcation of the presence of methylated
FMR1 DNA. FMR1 DNA methylation-positive males were
then tested for CGG repeat length by PCR ampliﬁcation
and by Southern blot analysis. A sample was considered
to be from a KS male if two X chromosomes were detected
by Southern analysis (as a typical female pattern), CGG
repeat analysis (two different CGG repeat alleles detected),
and/or semiquantitative amelogenin PCR. The remaining
samples were tested by Southern blotting for FMR1 full
mutations.
Of 821 pools screened, representing 36,124 newborns
recorded as males, 650 pools had no detectable methylated
FMR1 DNA and were called negative (28,600 newborns).
Among the 171 pools with FMR1 DNA methylation, 177
newborns were identiﬁed, with several pools having
multiple positives. Of these, 113 newborns (63%) were
determined to be females via amelogenin PCR, and the
majority of these probably reﬂect clerical errors on the
part of the delivery hospitals in the state. Of the 64 males
with methylated FMR1 DNA, seven were conﬁrmed to
carry the full mutation at FMR1, by Southern blot analysis,
and 57 were found to have KS. A representative Southern
blot of one of the FXS males identiﬁed by Q-MSP is shown
in Figure 6. From these data, we estimate the incidence of
FXS in the general population to be 1 in 5161 males (95%
CI: 1 in 10,653–1 in 2500) and the incidence of KS to be
1 in 634 males (95% CI: 1 in 821–1 in 489).
Using the reported racial and ethnic information for
each sample, we calculated the incidence of FXS and KS
among the various groups (Table 1). Of 16,252 samples
from white males, four had FXS and 27 had KS. Of
10,979 samples from African American males, two hadican Journal of Human Genetics 85, 503–514, October 9, 2009 509
FXS and 20 had KS. Of 5396 samples from Hispanic males,
one had FXS and three had KS. No FXS males were identi-
ﬁed among the 848 Asian, 87 American Indian, and 779
multiracial males tested or among the samples identiﬁed
as unknown or unmarked. Three KS males were identiﬁed
among the 848 Asian male samples screened.
Discussion
Here, we report a quantitative, methylation-sensitive PCR
assay that is an effective and inexpensive method of pop-
ulation screening for FXS males. The assay is amenable
for adaptation to a high-throughput format that can be
used for detecting FMR1 methylation in individual male
dried blood samples. Alternatively, the sensitivity of the
method allows for pooling of male dried blood spot
samples into large groups, reducing the labor and expense
for screening. With pooling, we estimate the cost of the
screening, including labor and reagents, to be under $3
per sample.
Our approach can also be used as a way of screening for
full-mutation females. Approximately 82% of females who
carry the full mutation have elevated FMR1 DNA methyla-
tion, deﬁned as greater than 2 SD above the mean of
normal methylation. Thus, the positive predictive value
of identifying the full-mutation genotype in females is
97%; however, only about 41% of the full mutations in
these females are destined to be penetrant.24 Relative to
phenotype in full-mutation females, this approach did not
easily distinguish penetrant from nonpenetrant females.
Here, 80% of unaffected females with the full mutation
had elevated FMR1 DNA methylation, indistinguishable
from affected females. This could be problematic, because
revealing a potential diagnosis to parents when the full
mutation is destined to be nonpenetrant in their child
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Figure 6. Southern Blot with the Use of DNA Isolated from the
Dried Blood Spot Card from One of the FXS Males Identified in
the Screen, Sample 1419F10
Lane 1. normal male control. Lane 2. sample 1419F10. Lane 3.
normal female control. Lane 4. FXS genomic DNA control. Lane
5. molecular weight marker.510 The American Journal of Human Genetics 85, 503–514, Octobercould affect the parents’ perception of their child’s health,
lead to parental stress, and affect the parent-child relation-
ship, all of which have been well documented in cases
when false-positive diagnoses have been made during
newborn screening for metabolic disease, leading to
‘‘vulnerable child syndrome’’ or the ‘‘nocebo phenom-
enon,’’ when the expectation of sickness in an otherwise
normal child leads to a parental emotional response that
can itself lead to illness or distress.27 However, this
outcome would need to be balanced by the view that by
not identifying newborn girls with the full mutation, those
girls who will be affected with symptoms of FXS may not
be given either palliative early-intervention treatment or,
if effective pharmaceuticals are developed for FXS, a signif-
icant chance of an improved outcome.
To test the feasibility of using this approach as a newborn
screen for FXS, we screened 36,124 deidentiﬁed male dried
blood spot samples from the state of Georgia’s newborn
screening program. Because the assay identiﬁes males
with KS as well, owing to the FMR1 methylation of their
Table 1. Racial and Ethnic Distribution of Identified Males with
FXS and KS
Number
of Samples
(Percentage
of Population) Positives Incidence 95% CI
FXS
White 16,252 (45%) 4 1/4063 1/10,477–1/1580
African
American
10,979 (30%) 2 1/5490 1/20,017–1/1506
Hispanic 5396 (15%) 1 1/5396 1/30,567– 1/953
Asian 847 (2%) 0
American
Indian
86 (< 1%) 0
Multiracial 778 (2%) 0
Unknown 343 (1%) 0
Unmarked 1440 (4%) 0
TOTAL 36,124 (100%) 7 1/5161 1/10,653–1/2500
KS
White 16,252 (45%) 27 1/602 1/876–1/414
African
American
10,979 (30%) 20 1/549 1/848–1/356
Hispanic 5396 (15%) 3 1/1799 1/5288–1/612
Asian 847 (2%) 3 1/282 1/830–1/97
American
Indian
86 (< 1%) 0
Multiracial 778 (2%) 0
Unknown 343 (1%) 0
Unmarked 1440 (4%) 4 1/360 1/925–1/140
TOTAL 36,124 (100%) 57 1/634 1/821–1/4899, 2009
inactive X chromosome, we also identiﬁed 57 males with
KS, yielding a general population incidence of 1 in 634
(95% CI: 1 in 821–1 in 489). A study by Nielsen et al.,
surveying 34,910 newborns over a 13 yr period in
Denmark, estimated the incidence of KS to be 1 in 576
boys,28 statistically indistinguishable from our estimate
(p ¼ 0.79; Chi-square test with Yates correction). Other
estimates of KS range from 1 in 1087 to 1 in 333 live
male births.29–38 It has been suggested that the incidence
of KS has increased in recent years, and the incidence
estimate from these recent studies combined is 1.72 per
1000 (1 in 581) male births,36 similar to our estimate of
1 in 634. Given that the population incidence of KS has
been more thoroughly studied than FXS and the amount
of FMR1 DNA methylation is considerably lower in KS
males than in FXS males (Figure 2), the detection of KS
males was, in this study, an important internal control
for FXS full-mutation screening, because KS incidence
served as a sentinel suggesting that our ascertainment
was unbiased.
Among the three main racial or ethnic groups repre-
sented in the state of Georgia, namely whites, African
Americans, and Hispanics, the incidence of KS was approx-
imately equal among whites (1 in 602) and African
Americans (1 in 549) but was less frequent among
Hispanics (1 in 1799). However, given the relatively small
numbers of Hispanic KS males identiﬁed, the paucity of
KS in this ethnic group suggested a lower incidence but was
not signiﬁcant from other ethnicities (p¼ 0.06; Chi-square
test with Yates correction). To our knowledge, there have
been no previous incidence estimates of KS speciﬁcally
among Hispanics. Maternal age may be a contributing fac-
tor, given that the average maternal age among Hispanics
in Georgia is about two years younger than the average
maternal age among African Americans and about four
years younger than that of white mothers (data taken
from the National Down Syndrome Project).39 Additional
studies with larger sample numbers are needed for veriﬁca-
tion that there is truly a decreased incidence of KS among
Hispanics.
The incidences of FXS among the three main racial or
ethnic groups in the state of Georgia were not statistically
different, with an incidence of 1 in 4063 in whites, an inci-
dence of 1 in 5490 in African Americans, and an incidence
of 1 in 5396 in Hispanics. However, these sample sizes are
too small to allow a deﬁnitive conclusion that there is not
a signiﬁcant difference in the incidence of FXS, and addi-
tional studies with larger cohorts are needed for deter-
mining whether FXS is truly equally prevalent among
these groups. The overall population incidence estimate
of 1 in 5161 from this study is similar to the prevalence
estimate from the largest of the studies using targeted
populations, which yielded an incidence estimate of 1 in
5530.15 Two large, direct, general population screens,
both using a series of dried blood spot samples from Spain,
identiﬁed two males with full mutations out of approxi-
mately 5000 samples screened. A study by Rife et al. iden-The Amertiﬁed two apparent full-mutation-carrying males by lack of
ampliﬁcation of the CGG repeat, yielding an incidence
estimate of 1 in 2466.40 A more recent study by Fernan-
dez-Carvajal et al. using dried blood spots from the north-
west region of Spain, identiﬁed two FXS males out of 5267,
yielding an incidence estimate of 1 in 2633 (95% CI: 1 in
10,000–1 in 714).19 However, given the relatively small
sample size of both of these studies, the differences in inci-
dence estimates between our study and the two Spanish
studies were not statistically signiﬁcant (p ¼ 0.67 and
p ¼ 0.72, respectively; Chi-square test with Yates correc-
tion). Saul et al. conducted a prospective study of FXS
screening, using 1459 samples that were ascertained
immediately after birth from volunteers from two South
Carolina hospitals.41 They identiﬁed two full-mutation-
carrying males among this cohort. Because of the limited
sample size and of how the samples were ascertained, the
authors concluded that high prevalence of FXS among
this cohort was probably a chance occurrence. Because
the study reported here is by far the largest undertaken
for FXS, and because the outcome compares favorably
with the largest indirect study of a targeted population,
our incidence of 1 in 5161 males is probably a close
approximation of the true incidence of FXS.
FXS has been proposed as a prototype for population
screening,42 and our methodology lends itself well to
newborn or infant screening. Identifying FXS in the
newborn period or in early infancy would enable early
intervention for these children. In addition, if the pharma-
ceutical therapies currently in clinical trials demonstrate
any efﬁcacy, identifying children with FXS would allow
them to be treated earlier, maximizing the possible beneﬁts
of these agents.43,44 Furthermore, identiﬁcation of FXS
children in a newborn screen would also prevent the
stress and anxiety, in addition to the monetary costs,
that parents incur in their ‘‘diagnostic odyssey,’’ which at
present translates to three or four years spent in order to
a diagnosis of FXS.45–47 Also, through cascade testing,
identifying children with full mutations would lead to
the identiﬁcation of mothers with premutations and of
clinically unrecognized full-mutation-carrying mothers.
These women could be counseled appropriately about
the risks of FXS in future pregnancies. In addition, these
women, as well as other members of their family, could
be counseled about their risks of premature ovarian failure
and FXTAS. A limitation of the study is the detection of
FXS among females. Although 82% of full-mutation-
carrying females could be identiﬁed by Q-MSP, our assay
could not distinguish those diagnosed with intellectual
disabilities and those without.
We must note that this methodology would not lead to
the identiﬁcation of premutation carriers in infant males,
because premutation FMR1 DNA is not hypermethylated.
Therefore, males who are at risk of developing FXTAS, an
adult-onset disorder, would not be identiﬁed as infants.
An alternative method, CGG repeat tract sizing, has also
been proposed for newborn screening for FXS. Thisican Journal of Human Genetics 85, 503–514, October 9, 2009 511
methodology would reveal premutation alleles, identi-
fying infants who are at risk of developing FXTAS. The
ethical consequences of screening newborns for adult-
onset neurodegenerative diseases has been debated exten-
sively, and two committees of the American Academy of
Pediatrics have recommended against predictive testing
for adult-onset disorders in persons under 18 years.48,49
However, identiﬁcation of premutation males would iden-
tify a mother at risk for future full-mutation pregnancies,
as well as families with pre- and full-mutation individuals.
As with the debate over screening full-mutation-carrying
females without being prognostic, screening for only full
mutations or for premutations also deserves further
consideration.
Both FMR1 DNA methylation analysis and CGG repeat
tract sizing will lead to the identiﬁcation of KS males
in newborn or infant screening. The same arguments
that are used to support screening for FXS, early interven-
tion and preventing the diagnostic odyssey, also apply to
KS. However, those with KS have relatively mild pheno-
typic features that may present clinically at many points
during the course of their life,50 and they are often undiag-
nosed their entire lives, although this is due to variable
expressivity or mosaicism rather than to nonpenetrance,
because nearly all KS males are infertile.51 Whether or
not revealing a diagnosis of KS from a newborn screen
for FXS is appropriate merits further debate, similar to
screening for premutations or for full mutations in
females.
In summary, we describe here a highly sensitive and
speciﬁc assay for methylated FMR1 DNA that is cost effec-
tive and carries sufﬁcient high-throughput capability to
serve as a population screening method for FXS in male
newborns. Although the approach also identiﬁed full
mutations in females, it is not prognostic in these females.
We utilized this approach to screen 36,124 deidentiﬁed
dried blood spots from newborn males and demonstrate
the incidence of FXS to be 1 in 5161 males. Given the
size of this screen, this probably represents the true male
incidence of FXS in the United States.
Supplemental Data
Supplemental Data include two ﬁgures and can be found with this
article online at http://www.cell.com/AJHG/.
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